Pharvaris (PHVS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharvaris, a Dutch biopharmaceutical company, has executed the second amendment to its License Agreement with Germany’s BRAIN Biotech AG, effective September 20, 2024. The amendment facilitates the sale of BRAIN Biotech’s revenue rights from Pharvaris to Royalty Pharma and clarifies terms regarding the duration of Pharvaris’s payment obligations. This adjustment reflects an ongoing commitment to managing their intellectual property and financial strategy in the pharmaceutical industry.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
